Study of the Safety and Efficacy of STI-6643 in Subjects With Advanced Solid Tumors

  • End date
    Dec 2, 2022
  • participants needed
  • sponsor
    Sorrento Therapeutics, Inc.
Updated on 2 December 2021


This is a first-in-human, phase 1, open-label, dose-escalation study of STI-6643 administered by intravenous infusion in subjects with a relapsed/refractory advanced solid tumor.


This is a first-in-human, phase 1, open-label, dose-escalation study of STI-6643 administered by intravenous infusion in subjects with a relapsed/refractory advanced solid tumor.

The study will determine an MTD and RP2D using a conventional 3+3 study design with dose limiting toxicity evaluated over the initial 28 days of STI-6643 administration.

The schedule of STI-6643 administration will be weekly for the initial 4 weeks of a 5-week cycle and then every 2 weeks thereafter (i.e., starting with Cycle 2) of a 4-week cycle. Subjects will continue to receive STI-6643 in the absence of progression or unacceptable toxicity. Subjects with minimal toxicity will have the option of decreasing the frequency of their clinic visits during later cycles.

Condition Relapsed Solid Neoplasm, Solid Tumors, Solid Neoplasm, Solid Tumour, Refractory Tumor, Solid Tumor
Treatment STI-6643
Clinical Study IdentifierNCT04900519
SponsorSorrento Therapeutics, Inc.
Last Modified on2 December 2021


Yes No Not Sure

Inclusion Criteria

ECOG Performance Status <= 2
Histologically cytologically confirmed solid tumor
Relapsed, is refractory to, or intolerant of standard of care therapy
No available approved therapy that may provide clinical benefit per Investigator
Measurable or evaluable disease by RECISTv1.14
Life expectancy of > 12 weeks per Investigator
Willingness to comply with the study schedule and all study requirements

Exclusion Criteria

Participating in any other interventional clinical study
Previous exposure to an anti-CD47 or SIRP antibody
days (or 5 half-lives if shorter) between of systemic anti-tumor treatment (e.g., chemotherapy, endocrine therapy, immunotherapy, cellular therapy) and C1D1
days from prior irradiation ( 7 days from limited field irradiation for control of symptoms) and C1D1
Known central nervous system (CNS) involvement with tumor (e.g., metastases, meningeal carcinomatosis)
Active second malignancy requiring ongoing systemic treatment
History of primary immunodeficiency disorders
History of active pulmonary tuberculosis
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note